Sep 2026· Journal of Proteome Research· Vol 25, pp. 5091 - 5102· 0 citations· 28 references
TL;DR
A modular mass spectrometry-based assay for the analysis of orthologous proteins across species in the context of translational science using ataxin-2 (ATXN2) as an example provides a translational blueprint that can be adapted to other orthologues, reducing cost and timeline in drug development.
Abstract
Unequivocal identification and reproducible quantitation of proteins are key components of research and development activity in drug discovery. In some cases, the target protein might be a protein highly conserved across species; antibody-based assays are not specific enough to discriminate between orthologues, thus forcing drug developers to use multiple analytical platforms across preclinical models. Here, we present a modular mass spectrometry-based assay for the analysis of orthologous proteins across species in the context of translational science using ataxin-2 (ATXN2) as an example. Instead of relying on recombinant proteins, we applied rational peptide design to target human, mouse, human/pig/non-human primates (NHP), or pan-species regions of the full-length protein. Specificity and sensitivity of the method were proven in wild-type and transgenic models. Dose–response upon treatment with different doses of an adeno-associated virus (AAV)-delivering microRNA (miRNA) targeting ATXN2 showed that knock-down at the transcript level was consistent with downregulation at the protein level, confirming the assay suitability for target engagement evaluation. Furthermore, the data presented here indicate that this method is readily transferable to minipigs, ensuring analytical continuity across preclinical studies. More broadly, this work provides a translational blueprint that can be adapted to other orthologues, reducing cost and timeline in drug development.
A high-throughput assay to identify small molecules that specifically inhibit a protein of interest in its nascent-chain form in its nascent-chain form is presented, providing a robust platform for larger-scale screening campaigns.
P. Fischer, Sebastian Hiller· bioRxiv· 0 citations
The sequence and structural similarity between Drosophila and human proteins was examined to address the question of whether Drosophila proteins can be used as human surrogates for early drug discovery, and it was hypothesized that the sequence identity within the drug binding pocket of D. melanogaster proteins would e...
Anjali Shankar, R. Karki· Journal of emerging investig...· 0 citations
Advances establish PROTAC technology as a transformative platform in modern drug discovery while emphasizing the scientific and translational challenges that must be addressed to enable broader clinical application.
S. Badadhe, Vikas B. Gawali, Mahesh D. Bhalsing et al.· Discover Chemistry· 0 citations
Summary. Targeted protein degradation (TPD) is a modern strategy for developing new therapeutic agents that requires not only detection of decreased target abundance but also stepwise validation of the compound’s mechanism of action. In this approach, the disappearance of the target protein is necessary but insufficien...
O. Vasylchenko, T. Trokhymchuk, M. Arkhypova et al.· Preventive medicine. Theory...· 0 citations
Proteomics strategies are discussed, which enable the profiling of adverse drug reactions, the dissection of resistance mechanisms, and the advancement of precision oncology in antitumor drug development and precision oncology.
Qiang-Feng Zhong, Xiu-Li Wu, E. Wiechec et al.· Drug Design, Development and...· 0 citations
This work presents a modular, multiscale computational platform integrating two complementary mechanistic models covering the full pharmacological cascade of mRNA-based immunotherapies, and proposes this platform as a step toward the quantitative pharmacological framework that mRNA therapeutics currently lack.
E. Pettinà, F. A. Chahine, E. Campanile et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.